Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review.
Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review.
复制标题
DOI：
10.1016/j.jacc.2020.08.028
复制
发表时间：
2020-10-13
影响因子：
24
通讯作者：
Udell JA
中科院分区：
文献类型：
--
作者：
Behrouzi B;Araujo Campoverde MV;Liang K;Talbot HK;Bogoch II;McGeer A;Fröbert O;Loeb M;Vardeny O;Solomon SD;Udell JA
病毒性呼吸道感染是心血管疾病的危险因素。潜在的心血管疾病也与病毒性呼吸道感染后并发症的风险增加有关，包括发病率、死亡率和医疗保健使用率的增加。在全球范围内，季节性流感和当前的2019冠状病毒病（COVID-19）大流行都观察到这些现象。心血管疾病患者是呼吸道病毒疫苗的重要目标人群，在3个正在进行的大型流感疫苗心血管结局试验中，有能力确定流感疫苗的潜在心脏保护作用。在COVID-19背景下，这些国际试验网络可能具有独特的优势，可以重新部署基础设施，研究COVID-19一级和二级预防的治疗方法。在此，我们描述了流感和COVID-19感染与急性心血管事件风险之间的机制联系，总结了迄今为止关于流感疫苗潜在心脏保护作用的数据，并描述了正在进行的流感疫苗心血管结局试验，强调了适用于COVID-19的重要经验教训。病毒性呼吸道感染，如季节性流感和COVID-19，与心血管事件风险升高有关。几个国际cvot正在调查季节性流感疫苗是否能降低心衰或冠状动脉疾病患者心血管事件的风险。现有的试验网络可为评估有COVID-19并发症风险的心血管疾病患者的一级和二级预防策略提供机会。
Viral respiratory infections are risk factors for cardiovascular disease (CVD). Underlying CVD is also associated with an increased risk of complications following viral respiratory infections, including increased morbidity, mortality, and health care utilization. Globally, these phenomena are observed with seasonal influenza and with the current coronavirus disease 2019 (COVID-19) pandemic. Persons with CVD represent an important target population for respiratory virus vaccines, with capacity developed within 3 large ongoing influenza vaccine cardiovascular outcomes trials to determine the potential cardioprotective effects of influenza vaccines. In the context of COVID-19, these international trial networks may be uniquely positioned to redeploy infrastructure to study therapies for primary and secondary prevention of COVID-19. Here, we describe mechanistic links between influenza and COVID-19 infection and the risk of acute cardiovascular events, summarize the data to date on the potential cardioprotective effects of influenza vaccines, and describe the ongoing influenza vaccine cardiovascular outcomes trials, highlighting important lessons learned that are applicable to COVID-19. Viral respiratory infections, such as seasonal influenza and COVID-19, are associated with elevated risks of cardiovascular events. Several international CVOTs are investigating whether seasonal influenza vaccine reduces the risk of cardiovascular events among patients with HF or coronary artery disease. Existing trial networks may provide an opportunity to assess primary and secondary prevention strategies for patients with CVD at risk of complications from COVID-19.
登录
查看更多内容
影响因子：
168.9
作者：
Chan, Jasper Fuk-Woo;Yuan, Shuofeng;Yuen, Kwok-Yung
通讯作者：
Yuen, Kwok-Yung
DOI：
10.1186/cc8208
发表时间：
2009
期刊：
Critical care (London, England)
影响因子：
--
作者：
Bermejo-Martin JF;Ortiz de Lejarazu R;Pumarola T;Rello J;Almansa R;Ramírez P;Martin-Loeches I;Varillas D;Gallegos MC;Serón C;Micheloud D;Gomez JM;Tenorio-Abreu A;Ramos MJ;Molina ML;Huidobro S;Sanchez E;Gordón M;Fernández V;Del Castillo A;Marcos MA;Villanueva B;López CJ;Rodríguez-Domínguez M;Galan JC;Cantón R;Lietor A;Rojo S;Eiros JM;Hinojosa C;Gonzalez I;Torner N;Banner D;Leon A;Cuesta P;Rowe T;Kelvin DJ
通讯作者：
Kelvin DJ
影响因子：
5.3
作者：
Bermudez-Fajardo, Alexandra;Oviedo-Orta, Ernesto
通讯作者：
Oviedo-Orta, Ernesto
影响因子：
39.3
作者：
Ciszewski, Andrzej;Bilinska, Zofia T.;Ruzyllo, Witold
通讯作者：
Ruzyllo, Witold
影响因子：
5.5
作者：
Bouvier NM;Palese P
通讯作者：
Palese P